NICE Rejects Tecentriq For Small-Cell Lung Cancer In England
Uncertainties Remain Over Long-Term Effectiveness
Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.
